[Docetaxel as a component in the combined therapy of locally advanced squamous cell carcinoma of the glottis and oral cavity].
Two modalities of chemoradiotherapy for locally advanced squamous cell cancer of oro-hypopharynx and oral cavity were compared in the treatment of 34 patients. Five-year survival after cisplatin, 5-FU, taxotere, and carboplatin plus irradiation with TTD of 68-72 Gy (group 1) was 59.5% versus 13.8% without taxotere (group 2). Relapse was in 9 cases (60%) (4 - group 1 and 5 - group 2). Post-therapeutic complication stage III-IV was 57.8% (group 1) and 48% (group 2).
S B
SB
Alieva
S I
SI
Tkachev
I S
IS
Romanov
I A
IA
Zaderenko
S A
SA
Tiuliandin
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005931:Glottis; D006801:Humans; D053208:Kaplan-Meier Estimate; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D009367:Neoplasm Staging; D017671:Platinum Compounds / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D017671:Platinum Compounds; D043823:Taxoids; D000077143:Docetaxel; D005472:Fluorouracil